[Paper-level Aggregated] PMCID: PMC4385014

Evidence Type(s): Predictive

Summary: Mutation: L858R | Summary: The L858R mutation is associated with both sensitivity and reduced sensitivity to the anti-proliferative effect of erlotinib, indicating a complex predictive relationship with therapy response.

Evidence Type: Predictive Mutation: T790M | Summary: The T790M mutation, when present alongside L858R, is evaluated for sensitivity to erlotinib and is also associated with reduced sensitivity to erlotinib treatment in the NCI-H1975 cell line, suggesting a predictive relationship with therapy response and resistance.

Gene→Variant (gene-first): EGFR(1956):L858R EGFR(1956):T790M

Genes: EGFR(1956)

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: RESULTS PassageIndex: 3

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: L858R | Summary: The L858R mutation is associated with reduced sensitivity to erlotinib treatment in the NCI-H1975 cell line, indicating a correlation with resistance to this therapy. Evidence Type: Predictive | Mutation: T790M | Summary: The T790M mutation is associated with reduced sensitivity to erlotinib treatment in the NCI-H1975 cell line, indicating a correlation with resistance to this therapy.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: L858R | Summary: The L858R mutation is associated with sensitivity to the anti-proliferative effect of erlotinib, indicating a predictive relationship with therapy response. Evidence Type: Predictive | Mutation: T790M | Summary: The T790M mutation, when present alongside L858R, is also evaluated for sensitivity to erlotinib, suggesting a predictive relationship with therapy response.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M

[Paper-level Aggregated] PMCID: PMC4385014

Evidence Type(s): Oncogenic, Predictive

Justification: Oncogenic: The L858R and T790M mutations in the EGFR gene are associated with altered sensitivity to erlotinib, indicating their role in promoting cancer cell proliferation and resistance to treatment. Predictive: The presence of the L858R and T790M mutations in NSCLC cell lines correlates with varying sensitivity to erlotinib, suggesting that these mutations can predict the response to this targeted therapy.

Gene→Variant (gene-first): EGFR(1956):L858R EGFR(1956):T790M

Genes: EGFR(1956)

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: RESULTS PassageIndex: 3

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the sensitivity of different cell lines to erlotinib treatment, indicating that the presence of the L858R and T790M mutations correlates with reduced sensitivity to the drug, which is a predictive relationship regarding therapy response. Oncogenic: The L858R and T790M mutations are described in the context of their presence in NSCLC cell lines, suggesting their role in tumor development or progression, which aligns with the definition of oncogenic variants.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the sensitivity of NSCLC cell lines with specific EGFR mutations (L858R and T790M) to the anti-proliferative effect of erlotinib, indicating a correlation with treatment response. Oncogenic: The presence of the L858R and T790M mutations in the cell lines suggests that these somatic variants contribute to tumor development or progression, as they are associated with specific cancer cell lines.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: RESULTS PassageIndex: 3

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the sensitivity of different cell lines to erlotinib treatment, indicating that the presence of the L858R and T790M mutations correlates with reduced sensitivity to the drug, which is a predictive relationship regarding therapy response. Oncogenic: The L858R and T790M mutations are described in the context of their presence in NSCLC cell lines, suggesting their role in tumor development or progression, which aligns with the definition of oncogenic variants.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M

[Paragraph-level] PMCID: PMC4385014 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the sensitivity of NSCLC cell lines with specific EGFR mutations (L858R and T790M) to the anti-proliferative effect of erlotinib, indicating a correlation with treatment response. Oncogenic: The presence of the L858R and T790M mutations in the cell lines suggests that these somatic variants contribute to tumor development or progression, as they are associated with specific cancer cell lines.

Gene→Variant (gene-first): 1956:L858R 1956:T790M

Genes: 1956

Variants: L858R T790M